Medical test manufacturer Oxford Immunotec, based in the United Kingdom and Marlborough, has received U.S. Food and Drug Administration approval to use its tuberculosis test on children aged two years or older, the company announced on Tuesday.
“This clearance fills an unmet need, as many pediatric patients are still TB-screened using the antiquated tuberculin skin test,” said Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec.
With the T-SPOT TB test, patients need only visit the doctor’s office once to be tested for tuberculosis, Wrighton-Smith said, which is especially important as the coronavirus pandemic wears on.
The T SPOT TB test is available through Marlborough-based Quest Diagnostics and regional laboratory partners.
